MCID: PDT021
MIFTS: 34

Pediatric Osteosarcoma

Categories: Bone diseases, Cancer diseases

Aliases & Classifications for Pediatric Osteosarcoma

MalaCards integrated aliases for Pediatric Osteosarcoma:

Name: Pediatric Osteosarcoma 12 14
Childhood Osteosarcoma 69

Classifications:



External Ids:

Disease Ontology 12 DOID:3361
NCIt 46 C6585
UMLS 69 C1332986

Summaries for Pediatric Osteosarcoma

MalaCards based summary : Pediatric Osteosarcoma, also known as childhood osteosarcoma, is related to methotrexate toxicity or dose selection and transcobalamin ii deficiency. An important gene associated with Pediatric Osteosarcoma is SLC19A1 (Solute Carrier Family 19 Member 1), and among its related pathways/superpathways are Metabolism of water-soluble vitamins and cofactors and Selenium Micronutrient Network. The drugs Denosumab and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include bone, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Related Diseases for Pediatric Osteosarcoma

Graphical network of the top 20 diseases related to Pediatric Osteosarcoma:



Diseases related to Pediatric Osteosarcoma

Symptoms & Phenotypes for Pediatric Osteosarcoma

GenomeRNAi Phenotypes related to Pediatric Osteosarcoma according to GeneCards Suite gene sharing:

25 (show all 16)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-119 9.85 ROCK1
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-148 9.85 ROCK1
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 9.85 MTHFR
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-173 9.85 MTHFR ROCK1 EDN1
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-180 9.85 MTHFR
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 9.85 EDN1
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-211 9.85 ROCK1
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-216 9.85 ROCK1
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-27 9.85 DHFR
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-33 9.85 MTHFR
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-58 9.85 EDN1
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-68 9.85 MTHFR
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-77 9.85 MTHFR
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-86 9.85 MTHFR DHFR
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 9.85 MTHFR DHFR EDN1
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-95 9.85 MTHFR

MGI Mouse Phenotypes related to Pediatric Osteosarcoma:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 embryo MP:0005380 9.55 SLC19A1 DHFR EDN1 HK2 RFC1
2 growth/size/body region MP:0005378 9.5 ROCK1 SLC19A1 DHFR EDN1 HK2 MTHFR
3 mortality/aging MP:0010768 9.17 ROCK1 SLC19A1 DHFR EDN1 HK2 MTHFR

Drugs & Therapeutics for Pediatric Osteosarcoma

Drugs for Pediatric Osteosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 36)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Denosumab Approved Phase 2 615258-40-7
2
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
3 Antibodies Phase 2
4 Bone Density Conservation Agents Phase 2
5 Immunoglobulins Phase 2
6 Pharmaceutical Solutions Phase 2
7
Carboplatin Approved 41575-94-4 10339178 38904 498142
8
Doxorubicin Approved, Investigational 23214-92-8 31703
9
Gemcitabine Approved 95058-81-4 60750
10
Ifosfamide Approved 3778-73-2 3690
11
Mechlorethamine Approved, Investigational 51-75-2 4033
12
Mesna Approved, Investigational 3375-50-6 598
13
Methotrexate Approved 1959-05-2, 59-05-2 126941
14
Folic Acid Approved, Nutraceutical, Vet_approved 59-30-3 6037
15
leucovorin Approved, Nutraceutical 58-05-9 143 6006
16
Doxil Approved June 1999 31703
17 Alkylating Agents
18 Anti-Bacterial Agents
19 Antibiotics, Antitubercular
20 Anti-Infective Agents
21 Antimetabolites
22 Antimetabolites, Antineoplastic
23 Antimitotic Agents
24 Antirheumatic Agents
25 Antiviral Agents
26 Dermatologic Agents
27 Folic Acid Antagonists
28 Immunosuppressive Agents
29 Isophosphamide mustard 0
30 Nucleic Acid Synthesis Inhibitors
31 Protective Agents
32 razoxane
33 Topoisomerase Inhibitors
34 Vitamin B Complex
35 Folate Nutraceutical
36 Vitamin B9 Nutraceutical

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma Recruiting NCT02470091 Phase 2
2 Phase 2 Study of Inhaled Lipid Cisplatin in Pulmonary Recurrent Osteosarcoma Active, not recruiting NCT01650090 Phase 2 Inhaled Lipid Cisplatin (ILC)
3 The Impact of Cancer on the Physical and Psychosocial Well-being Among Childhood Osteosarcoma Survivors Recruiting NCT03298971
4 Phase I Clinical Trial of GRID Therapy in Pediatric Osteosarcoma of the Extremity Recruiting NCT03139318
5 Doxorubicin With Cisplatin, High-Dose Methotrexate, and Additional Risk-Adapted Outpatient Chemotherapy Terminated NCT00673179 Doxorubicin;Cisplatin;Methotrexate;Leucovorin;Dexrazoxane;Ifosfamide;Gemcitabine;Sargramostim;Mesna

Search NIH Clinical Center for Pediatric Osteosarcoma

Genetic Tests for Pediatric Osteosarcoma

Anatomical Context for Pediatric Osteosarcoma

MalaCards organs/tissues related to Pediatric Osteosarcoma:

38
Bone

Publications for Pediatric Osteosarcoma

Articles related to Pediatric Osteosarcoma:

(show top 50) (show all 81)
# Title Authors Year
1
Prognostic Value of Metabolic and Volumetric Parameters of FDG PET in Pediatric Osteosarcoma: A Hypothesis-generating Study. ( 29357275 )
2018
2
Biological function of microRNA-30c/SOX9 in pediatric osteosarcoma cell growth and metastasis. ( 29364496 )
2018
3
Endostar combined with chemotherapy in a pediatric osteosarcoma with pulmonary metastasis and malignant pleural effusion: A case report. ( 29390436 )
2017
4
Quantitative diffusion-weighted magnetic resonance imaging assessment of chemotherapy treatment response of pediatric osteosarcoma and Ewing sarcoma malignant bone tumors. ( 28806574 )
2017
5
Pediatric Osteosarcoma: An Updated Review. ( 28469335 )
2017
6
Immunotherapeutic approaches in pediatric osteosarcoma. ( 28353326 )
2017
7
ATIC Gene Polymorphism and Histologic Response to Chemotherapy in Pediatric Osteosarcoma. ( 28267080 )
2017
8
TRIM37 promotes tumor cell proliferation and drug resistance in pediatric osteosarcoma. ( 29163677 )
2017
9
Ambulatory High-dose Methotrexate Administration in Pediatric Osteosarcoma Patients at a Single Institution in Argentina. ( 28937522 )
2017
10
The expression and function of miRNA-106 in pediatric osteosarcoma. ( 28272712 )
2017
11
The role of the MTHFR C677T polymorphism in methotrexate-induced toxicity in pediatric osteosarcoma patients. ( 28592186 )
2017
12
Influence of genetic polymorphisms in the folate pathway on toxicity after high-dose methotrexate treatment in pediatric osteosarcoma. ( 27104192 )
2016
13
Efficacy of pamidronate in pediatric osteosarcoma patients with low bone mineral density. ( 27104175 )
2016
14
CUL4A expression in pediatric osteosarcoma tissues and its effect on cell growth in osteosarcoma cells. ( 26715273 )
2016
15
Novel insights and therapeutic interventions for pediatric osteosarcoma. ( 27651036 )
2016
16
Pharmacological or genetic inhibition of LDHA reverses tumor progression of pediatric osteosarcoma. ( 27261617 )
2016
17
The Oncolytic Adenovirus VCN-01 as Therapeutic Approach Against Pediatric Osteosarcoma. ( 26603261 )
2016
18
Multimodality Imaging in Pediatric Osteosarcoma in the Era of Image Gently and Image Wisely Campaign With a Close Look at the CT Scan Radiation Dose. ( 26583624 )
2016
19
Bone mineral density change during adjuvant chemotherapy in pediatric osteosarcoma. ( 26512351 )
2015
20
PI3K/Akt signaling mediated Hexokinase-2 expression inhibits cell apoptosis and promotes tumor growth in pediatric osteosarcoma. ( 26116768 )
2015
21
Experience of Pediatric Osteosarcoma of the Extremity at a Single Institution in Taiwan: Prognostic Factors and Impact on Survival. ( 25323470 )
2014
22
Recurrent somatic structural variations contribute to tumorigenesis in pediatric osteosarcoma. ( 24703847 )
2014
23
Impaired testicular function after an ifosfamide-containing regimen for pediatric osteosarcoma: a case series and review of the literature. ( 24667129 )
2014
24
In silico functional analyses and discovery of survival-associated microRNA signatures in pediatric osteosarcoma. ( 25594070 )
2014
25
Pediatric Osteosarcoma: A Single Institution's Experience. ( 25365431 )
2014
26
Management of local recurrence of pediatric osteosarcoma following limb-sparing surgery. ( 24558066 )
2014
27
Comparative outcome of Thai pediatric osteosarcoma treated with two protocols: the role of high-dose methotrexate (HDMTX) in a single institute experience. ( 25520112 )
2014
28
Upregulated expression of microRNA-214 is linked to tumor progression and adverse prognosis in pediatric osteosarcoma. ( 24038809 )
2014
29
Bronchioloalveolar carcinoma as a second malignancy in a pediatric osteosarcoma survivor: case report. ( 23758793 )
2013
30
Carboplatin and doxorubicin in treatment of pediatric osteosarcoma: a 9-year single institute experience in the Northern Region of Thailand. ( 23621194 )
2013
31
Prognostic evaluation of microRNA-210 expression in pediatric osteosarcoma. ( 23430441 )
2013
32
Combined MicroRNA-340 and ROCK1 mRNA Profiling Predicts Tumor Progression and Prognosis in Pediatric Osteosarcoma. ( 24398981 )
2013
33
Pathological fracture as the presenting feature in pediatric osteosarcoma. ( 23281226 )
2013
34
Endothelin-1 gene polymorphisms and risk of chemoresistant pediatric osteosarcoma. ( 24123836 )
2013
35
Correlation of non-mass-like abnormal MR signal intensity with pathological findings surrounding pediatric osteosarcoma and Ewing's sarcoma. ( 22406919 )
2012
36
Case-parent analysis of variation in pubertal hormone genes and pediatric osteosarcoma: a Children's Oncology Group (COG) study. ( 23205180 )
2012
37
Serum tumor markers in pediatric osteosarcoma: a summary review. ( 22587902 )
2012
38
Plasma proteomic profiling of pediatric osteosarcoma. ( 22083817 )
2012
39
Clinical relations of methotrexate pharmacokinetics in the treatment for pediatric osteosarcoma. ( 22652833 )
2012
40
Survival outcomes of pediatric osteosarcoma and Ewing's sarcoma: a comparison of surgery type within the SEER database, 1988-2007. ( 22223058 )
2011
41
Primary pediatric osteosarcoma of the skull. ( 22134292 )
2011
42
Two pediatric osteosarcoma cases with delayed methotrexate excretion: its clinical course and management. ( 21509165 )
2011
43
Elevated expression of CXC chemokines in pediatric osteosarcoma patients. ( 20806347 )
2011
44
Location of pulmonary metastasis in pediatric osteosarcoma is predictive of outcome. ( 21763830 )
2011
45
Staged lengthening arthroplasty for pediatric osteosarcoma around the knee. ( 19885713 )
2010
46
Lengthening of intercalary allograft combined with free vascularized fibular graft after reconstruction in pediatric osteosarcoma of femur. ( 19950438 )
2010
47
Prognostic significance of early lymphocyte recovery in pediatric osteosarcoma. ( 20734401 )
2010
48
Ambulatory high-dose methotrexate administration among pediatric osteosarcoma patients in an urban, underserved setting is feasible, safe, and cost-effective. ( 20949591 )
2010
49
Proteomic analysis of chemonaive pediatric osteosarcomas and corresponding normal bone reveals multiple altered molecular targets. ( 19492781 )
2009
50
Methotrexate in pediatric osteosarcoma: response and toxicity in relation to genetic polymorphisms and dihydrofolate reductase and reduced folate carrier 1 expression. ( 19159907 )
2009

Variations for Pediatric Osteosarcoma

Expression for Pediatric Osteosarcoma

Search GEO for disease gene expression data for Pediatric Osteosarcoma.

Pathways for Pediatric Osteosarcoma

Pathways related to Pediatric Osteosarcoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.11 DHFR MTHFR SLC19A1
2
Show member pathways
11.67 DHFR MTHFR SLC19A1
3
Show member pathways
11.28 ATIC DHFR MTHFR
4 11.07 EDN1 HK2
5 10.42 ATIC DHFR MTHFR SLC19A1

GO Terms for Pediatric Osteosarcoma

Biological processes related to Pediatric Osteosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to amino acid GO:0043200 9.32 EDN1 MTHFR
2 tetrahydrofolate metabolic process GO:0046653 9.26 DHFR MTHFR
3 tetrahydrofolate biosynthetic process GO:0046654 9.16 ATIC DHFR
4 dihydrofolate metabolic process GO:0046452 8.96 ATIC DHFR
5 folic acid metabolic process GO:0046655 8.8 DHFR MTHFR SLC19A1

Molecular functions related to Pediatric Osteosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 catalytic activity GO:0003824 9.33 ATIC HK2 MTHFR
2 NADP binding GO:0050661 8.96 DHFR MTHFR
3 folic acid binding GO:0005542 8.62 DHFR SLC19A1

Sources for Pediatric Osteosarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....